Alnylam Pharmaceuticals, Inc. (ALNY)
Market: NASD |
Currency: USD
Address: 675 West Kendall Street
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Show more
📈 Alnylam Pharmaceuticals, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$324.82
-
Upside/Downside from Analyst Target:
4.00%
-
Broker Call:
41
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
10-25%
-
Net Income Growth Range (1Y):
10-25%
-
Revenue Growth Range (1Y):
10-25%
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Alnylam Pharmaceuticals, Inc.
| Date | Reported EPS |
|---|
| 2026-01-12 (estimated upcoming) | - |
| 2025-10-29 (estimated upcoming) | - |
| 2025-10-28 (estimated upcoming) | - |
| 2025-07-30 (estimated upcoming) | - |
| 2025-07-29 (estimated upcoming) | - |
| 2025-04-30 | - |
| 2025-04-29 | - |
| 2025-02-13 | -0.65 |
| 2025-01-12 | - |
| 2024-10-31 | -0.87 |
| 2024-08-01 | -0.13 |
| 2024-07-31 | -0.13 |
| 2024-05-02 | -0.52 |
| 2024-05-01 | -0.52 |
| 2024-02-15 | -1.1 |
| 2024-02-14 | -1.1 |
| 2023-11-02 | 1.15 |
| 2023-11-01 | 1.15 |
| 2023-08-03 | -2.21 |
| 2023-08-02 | -2.21 |
| 2023-05-04 | -1.4 |
| 2023-05-03 | -1.4 |
| 2023-02-23 | -1.68 |
| 2023-02-22 | -1.68 |
| 2022-10-27 | -2.69 |
| 2022-10-26 | -2.69 |
| 2022-07-28 | -2.29 |
| 2022-07-27 | -2.29 |
| 2022-04-28 | -2 |
| 2022-04-27 | -2 |
| 2022-02-10 | -2.16 |
| 2022-02-09 | -2.16 |
| 2021-10-28 | -1.64 |
| 2021-10-27 | -1.64 |
| 2021-08-03 | -1.61 |
| 2021-08-02 | -1.61 |
| 2021-04-29 | -1.71 |
| 2021-04-28 | -1.71 |
| 2021-02-11 | -2.09 |
| 2021-02-10 | -2.09 |
| 2020-11-05 | -2.18 |
| 2020-11-04 | -2.18 |
| 2020-08-06 | -1.56 |
| 2020-08-05 | -1.56 |
| 2020-05-06 | -1.83 |
| 2020-05-05 | -1.83 |
| 2020-02-05 | -2.57 |
| 2019-10-30 | -1.92 |
| 2019-08-05 | -1.93 |
| 2019-04-30 | -1.73 |
| 2019-02-06 | -2.09 |
| 2018-11-06 | -2.43 |
| 2018-08-01 | -1.83 |
| 2018-05-02 | -1.41 |
| 2018-02-07 | -1.48 |
| 2017-11-06 | -1.34 |
| 2017-08-08 | -1.34 |
| 2017-05-04 | -1.25 |
| 2017-02-07 | -1.32 |
| 2016-11-01 | -1.21 |
| 2016-08-03 | -1.05 |
| 2016-05-01 | -1.21 |
| 2016-02-10 | -1.07 |
| 2015-11-08 | -0.91 |
| 2015-08-05 | -0.85 |
| 2015-05-06 | -0.62 |
| 2015-02-11 | -0.28 |
| 2014-11-04 | -0.58 |
| 2014-08-06 | -0.58 |
| 2014-05-07 | -0.39 |
| 2014-02-12 | -0.51 |
| 2013-11-05 | -0.48 |
| 2013-08-07 | -0.29 |
| 2013-05-05 | -0.16 |
| 2013-02-06 | -0.46 |
| 2012-11-04 | -0.38 |
| 2012-08-05 | -0.25 |
| 2012-05-02 | -0.25 |
| 2012-02-08 | -0.33 |
| 2011-10-31 | -0.31 |
| 2011-07-31 | -0.33 |
| 2011-05-01 | -0.38 |
| 2011-02-16 | -0.16 |
| 2010-11-02 | -0.23 |
| 2010-08-03 | -0.35 |
| 2010-05-04 | -0.29 |
| 2010-02-24 | -0.19 |
| 2009-11-03 | -0.22 |
| 2009-08-05 | -0.55 |
| 2009-05-06 | -0.19 |
| 2009-02-23 | -0.23 |
| 2008-11-04 | -0.07 |
| 2008-08-05 | -0.31 |
| 2008-05-07 | -0.03 |
| 2008-02-06 | 0.04 |
| 2007-10-31 | -1.35 |
| 2007-08-08 | -0.34 |
| 2007-05-08 | -0.58 |
| 2007-02-06 | -0.26 |
| 2006-11-01 | -0.23 |
| 2006-07-25 | -0.31 |
| 2006-05-08 | -0.3 |
| 2006-02-14 | -0.56 |
| 2005-11-08 | -0.51 |
| 2005-08-02 | -0.54 |
| 2005-05-10 | -0.32 |
| 2005-02-14 | -0.29 |
| 2004-11-09 | -0.33 |
| 2004-08-03 | -1.1 |
📰 Related News & Research
No related articles found for "alnylam pharmaceuticals".
